Therefore, small molecule sst4 agonists with a completely new mechanism of action are under development for chronic neuropathic pain, concomitant mood disorders, and neurogenic inflammation that are still important unmet medical needs (Botz et al. 2017; Pintér et al. 2006; Scheich et al. 2016). Here, SSTR4 is linked to mood disorder.